IMI's bloodless cholesterol test indicates disease risk
This article was originally published in Clinica
A non-invasive, three-minute test that can measure cholesterol in the skin has proved to be an independent predictor of cardiovascular disease risk in a 125-patient US trial.
You may also be interested in...
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.